Marinus Pharmaceuticals Inc [NASDAQ: MRNS] gained 25.51% or 0.06 points to close at $0.32 with a heavy trading volume of 2690348 shares.
The daily chart for MRNS points out that the company has recorded -73.76% loss over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 2.63M shares, MRNS reached to a volume of 2690348 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Marinus Pharmaceuticals Inc [MRNS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNS shares is $1.47 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNS stock is a recommendation set at 2.56. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Marinus Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 23, 2024. The new note on the price target was released on August 14, 2024, representing the official price target for Marinus Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $20 to $2, while Robert W. Baird kept a Neutral rating on MRNS stock. On April 15, 2024, analysts decreased their price target for MRNS shares from 24 to 3.
The Average True Range (ATR) for Marinus Pharmaceuticals Inc is set at 0.04, with the Price to Sales ratio for MRNS stock in the period of the last 12 months amounting to 0.57.
Trading performance analysis for MRNS stock
Marinus Pharmaceuticals Inc [MRNS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.51. With this latest performance, MRNS shares dropped by -0.31% in over the last four-week period, additionally sinking by -73.76% over the last 6 months – not to mention a drop of -97.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNS stock in for the last two-week period is set at 47.70, with the RSI for the last a single of trading hit 64.74, and the three-weeks RSI is set at 39.61 for Marinus Pharmaceuticals Inc [MRNS]. The present Moving Average for the last 50 days of trading for this stock 0.4810, while it was recorded at 0.2573 for the last single week of trading, and 1.9933 for the last 200 days.
Marinus Pharmaceuticals Inc [MRNS]: A deeper dive into fundamental analysis
Marinus Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.47 and a Current Ratio set at 1.66.
An analysis of Institutional ownership at Marinus Pharmaceuticals Inc [MRNS]
There are presently around $83.04%, or 93.24%% of MRNS stock, in the hands of institutional investors. The top three institutional holders of MRNS stocks are: TANG CAPITAL MANAGEMENT LLC with ownership of 4.8 million shares, which is approximately 8.443%. SOFINNOVA INVESTMENTS, INC., holding 4.15 million shares of the stock with an approximate value of $$4.86 million in MRNS stocks shares; and SOFINNOVA INVESTMENTS, INC., currently with $$4.66 million in MRNS stock with ownership which is approximately 7%.
